302 related articles for article (PubMed ID: 17920160)
1. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.
Glodzik-Sobanska L; Pirraglia E; Brys M; de Santi S; Mosconi L; Rich KE; Switalski R; Saint Louis L; Sadowski MJ; Martiniuk F; Mehta P; Pratico D; Zinkowski RP; Blennow K; de Leon MJ
Neurobiol Aging; 2009 May; 30(5):672-81. PubMed ID: 17920160
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
4. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
[TBL] [Abstract][Full Text] [Related]
5. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
[TBL] [Abstract][Full Text] [Related]
7. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults.
Li G; Shofer JB; Petrie EC; Yu CE; Wilkinson CW; Figlewicz DP; Shutes-David A; Zhang J; Montine TJ; Raskind MA; Quinn JF; Galasko DR; Peskind ER
Alzheimers Res Ther; 2017 Jul; 9(1):48. PubMed ID: 28673336
[TBL] [Abstract][Full Text] [Related]
9. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
[TBL] [Abstract][Full Text] [Related]
11. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
Tapiola T; Pirttilä T; Mehta PD; Alafuzofff I; Lehtovirta M; Soininen H
Neurobiol Aging; 2000; 21(5):735-40. PubMed ID: 11016543
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
13. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
14. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
15. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
16. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
[TBL] [Abstract][Full Text] [Related]
17. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
18. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
19. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA
Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853
[TBL] [Abstract][Full Text] [Related]
20. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS).
Saunders TS; Jenkins N; Blennow K; Ritchie C; Muniz-Terrera G
EBioMedicine; 2022 Sep; 83():104241. PubMed ID: 36041266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]